🧪 Pipeline Progress (as of latest update):
NX-2127 & NX-5948 in Phase 1 🔬
NX-1607: Promising early clinical data in solid tumors
Multiple preclinical programs in immuno-oncology and autoimmune space
Down ~80% from highs (2021 biotech bubble burst 😬)
Consolidating near lows — potential bottom fishing zone 🐟
High short interest = possible squeeze setup 🔥
Speculative high-reward biotech. Great long-term potential if pipeline delivers. Suitable for risk-tolerant investors only. Not for the faint-hearted 🧠⚡
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.